Hexahydrokanabinol-O-acetát (HHC-O) · Sales discontinued in CZ
HHC-O acetate (often abbreviated as HHC-O) is an acetylated derivative of hexahydrocannabinol (HHC). It functions as a pro-drug – it changes into its fully active form only through metabolism in the human organism, similarly to THC-O acetate.
HHC-O is a semi-synthetic acetylated derivative of HHC. It falls under the same regulation as HHC and HHCP, distribution and sale for human consumption have been punishable in the CZ since 2025. Tato stránka slouží pouze jako informační zdroj a v naší nabídce HHC-O aktuálně nenajdete.
HHC-O acetate arises by acetylation of the hydroxyl group of the HHC molecule using acetic anhydride. By itself it has lower affinity at the CB1 receptor than the starting HHC, but after metabolism in the liver active HHC, or other hydroxylated metabolites that are strongly psychoactive, are released from it. This 'pro-drug' mechanism prolongs and amplifies the resulting effect. The raw material for HHC-O production was semi-synthetically prepared HHC, so the entire chain involved two laboratory transformations from hemp CBD.
HHC-O appeared on the European market in 2023 as a reaction to the growing popularity of HHC and the desire of users for stronger and longer effect. You will find it especially in the form of disposable vape pen cartridges, concentrates and enriched flowers. The main quality problems were low purity, fluctuating active substance content and, with inhaled forms, mainly safety risks associated with acetates.
Users describe HHC-O effects as strongly psychoactive with slower onset and substantially longer duration than classical HHC. Typical is deep relaxation, marked euphoria, sedation and changes in time perception. Onset after inhalation is described in 15–30 minutes, orally even longer, duration 5–8 hours. Side effects correspond to higher doses of psychoactive cannabinoids: tachycardia, paranoid states, dry mouth, red eyes, disorientation, acute intoxication in inexperienced users. With inhaled forms the main risk is the possible formation of ketene when heating acetates – the same topic that internationally criticized THC-O acetate. Clinical HHC-O studies in humans have not yet been published.
In the Czech Republic HHC-O is classified among prohibited psychoactive cannabinoids under the amendment to Act No. 167/1998 Coll. as worded in 2025. It falls under the same regulation as HHC, HHCP and 10-OH-HHC. Distribution, sale and possession for the purpose of distribution are punishable. HHC-O has the same status in most EU countries – France, Belgium, Austria, Germany and Italy have explicitly banned it. CBDsvět.cz does not and will not sell HHC-O – we consider its risk profile incompatible with our focus on verified CBD products.
Legislation is evolving. This text is not legal advice – for specific cases we recommend consulting a lawyer.
| Cannabinoid | Potency | Duration | Legality CZ |
|---|---|---|---|
| HHC | ≈ 70 % síly THC | 3–5 h | CZ – banned |
| HHC-O acetát | Vyšší než HHC, prodloužené | 5–8 h | CZ – banned |
| HHCP | 10–25× silnější než HHC | 4–6 h | CZ – banned |
| THC-O | ≈ 2–3× silnější než THC | 4–6 h | CZ – banned |
| CBD | Nepsychoaktivní | 4–6 h | Legal in EU |
HHC-O cannot currently be legally purchased in the Czech Republic. These products are fully legal and support the endocannabinoid system.
HHC-O is an acetylated derivative of HHC – a pro-drug that is metabolized in the human organism into active HHC and its hydroxylated metabolites. It is produced semi-synthetically from hemp CBD in two laboratory steps.
You might also be interested in